人血浆中XII因子的活化:苯并脒对高分子量激肽原辅助因子功能的保护作用。

K Briseid, H T Johansen
{"title":"人血浆中XII因子的活化:苯并脒对高分子量激肽原辅助因子功能的保护作用。","authors":"K Briseid,&nbsp;H T Johansen","doi":"10.1111/j.1600-0773.1983.tb03433.x","DOIUrl":null,"url":null,"abstract":"<p><p>By incubation of human citrated plasma with acetone 25% v/v kallikrein inhibitors were destroyed and prekallikrein activated to kallikrein. When the incubation was carried out in the presence of benzamidine 7 mM, the cofactor capacity of high molecular weight kininogen (HMrK) was protected against destruction by a serine protease which was not plasma kallikrein. By analogy with studies in rat plasma this protease might be a plasminogen activator (Berstad & Briseid 1982; Johansen & Briseid 1983). Factor XII in the plasma preparation was activated to unfragmented factor XIIa by adsorption to kaolin, and assayed as prekallikrein activator (PKA). The extent of activation of factor XII was only insignificantly influenced by the 1 + 1 (v/v) dilution of the plasma preparation with a suspension of kaolin. When, however, the preparation was diluted greater than 1 + 5 (v/v) before incubation with the suspension, a stoichiometric HMrK concentration-effect curve could be established, allowing the assay of cofactor-active HMrK. Assays of HMrK in plasma preparations from healthy men and women demonstrated an average lower level of cofactor-active HMrK in the preparations from women. It is suggested that benzamidine is not capable of providing a complete protection of HMrK during the procedure in all plasma samples.</p>","PeriodicalId":6972,"journal":{"name":"Acta pharmacologica et toxicologica","volume":"53 4","pages":"344-52"},"PeriodicalIF":0.0000,"publicationDate":"1983-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1600-0773.1983.tb03433.x","citationCount":"0","resultStr":"{\"title\":\"Activation of factor XII in human plasma: protection by benzamidine of the cofactor function of high molecular weight kininogen.\",\"authors\":\"K Briseid,&nbsp;H T Johansen\",\"doi\":\"10.1111/j.1600-0773.1983.tb03433.x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>By incubation of human citrated plasma with acetone 25% v/v kallikrein inhibitors were destroyed and prekallikrein activated to kallikrein. When the incubation was carried out in the presence of benzamidine 7 mM, the cofactor capacity of high molecular weight kininogen (HMrK) was protected against destruction by a serine protease which was not plasma kallikrein. By analogy with studies in rat plasma this protease might be a plasminogen activator (Berstad & Briseid 1982; Johansen & Briseid 1983). Factor XII in the plasma preparation was activated to unfragmented factor XIIa by adsorption to kaolin, and assayed as prekallikrein activator (PKA). The extent of activation of factor XII was only insignificantly influenced by the 1 + 1 (v/v) dilution of the plasma preparation with a suspension of kaolin. When, however, the preparation was diluted greater than 1 + 5 (v/v) before incubation with the suspension, a stoichiometric HMrK concentration-effect curve could be established, allowing the assay of cofactor-active HMrK. Assays of HMrK in plasma preparations from healthy men and women demonstrated an average lower level of cofactor-active HMrK in the preparations from women. It is suggested that benzamidine is not capable of providing a complete protection of HMrK during the procedure in all plasma samples.</p>\",\"PeriodicalId\":6972,\"journal\":{\"name\":\"Acta pharmacologica et toxicologica\",\"volume\":\"53 4\",\"pages\":\"344-52\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1983-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1111/j.1600-0773.1983.tb03433.x\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta pharmacologica et toxicologica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1111/j.1600-0773.1983.tb03433.x\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta pharmacologica et toxicologica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/j.1600-0773.1983.tb03433.x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

用25% v/v丙酮孵育人柠檬酸血浆,可破坏钾likrein抑制剂,使钾likrein预活化为钾likrein。当在7 mM苯甲脒的存在下孵育时,高分子量激肽原(HMrK)的辅助因子容量被一种非血浆激肽酶的丝氨酸蛋白酶保护而不被破坏。与在大鼠血浆中的研究类似,这种蛋白酶可能是纤溶酶原激活剂(Berstad & Briseid 1982;Johansen & Briseid 1983)。血浆制剂中的因子XII被高岭土吸附活化为未破碎因子XIIa,并作为预钾likrein活化剂(PKA)进行检测。高岭土悬浮液对血浆制剂的1 + 1 (v/v)稀释对因子XII的激活程度影响不显著。然而,当制剂在与悬浮液孵育前稀释大于1 + 5 (v/v)时,可以建立化学计量学HMrK浓度-效应曲线,从而可以检测辅因子活性HMrK。对健康男性和女性血浆制剂中HMrK的测定表明,女性血浆制剂中辅助因子活性HMrK的平均水平较低。提示苯脒不能在所有血浆样品中提供对HMrK的完全保护。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Activation of factor XII in human plasma: protection by benzamidine of the cofactor function of high molecular weight kininogen.

By incubation of human citrated plasma with acetone 25% v/v kallikrein inhibitors were destroyed and prekallikrein activated to kallikrein. When the incubation was carried out in the presence of benzamidine 7 mM, the cofactor capacity of high molecular weight kininogen (HMrK) was protected against destruction by a serine protease which was not plasma kallikrein. By analogy with studies in rat plasma this protease might be a plasminogen activator (Berstad & Briseid 1982; Johansen & Briseid 1983). Factor XII in the plasma preparation was activated to unfragmented factor XIIa by adsorption to kaolin, and assayed as prekallikrein activator (PKA). The extent of activation of factor XII was only insignificantly influenced by the 1 + 1 (v/v) dilution of the plasma preparation with a suspension of kaolin. When, however, the preparation was diluted greater than 1 + 5 (v/v) before incubation with the suspension, a stoichiometric HMrK concentration-effect curve could be established, allowing the assay of cofactor-active HMrK. Assays of HMrK in plasma preparations from healthy men and women demonstrated an average lower level of cofactor-active HMrK in the preparations from women. It is suggested that benzamidine is not capable of providing a complete protection of HMrK during the procedure in all plasma samples.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信